Femasys (FEMY) said Monday it has received 510(k) clearance from the US Food and Drug Administration for FemChec, a tool designed for controlled delivery of contrast to check the status of fallopian tubes.
It is part of the company's non-surgical permanent birth control method, dubbed FemBloc, Femasys said.
The company added that it will continue to work with the regulator as FemBloc moves through a late-stage trial that is currently enrolling.
Price: 1.07, Change: -0.01, Percent Change: -0.47
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。